Form FDA 2253 eCTD Checklist (Free PDF)
Form FDA 2253 eCTD checklist
What FDA’s eCTD validation rules check in a promotional labeling and advertising submission — the form, the labeling, the Module 1.15 attributes and the PDFs — with the rule number for each.
Form 2253 and Module 1.15
Promotional labeling and advertising for prescription drugs and biologics is submitted to FDA on Form 2253 when it is first used (21 CFR 314.81(b)(3)(i) for drugs, 601.12(f)(4) for biologics). It goes to OPDP at CDER or APLB at CBER as an eCTD sequence. The materials sit in Module 1.15, the one US section where the headings themselves carry required attributes: audience type, document type, material type and material ID.
Eight 2253 checks before you send
A preview of the 15 in the free checklist. Each one is an FDA eCTD validation rule.
- Form 2253 only — no other FDA form in a promotional submission. FDA 1553
- Labeling in 1.14.6 — the current product labeling, every time. FDA 1551
- Form and envelope agree — the application number on the form matches us-regional.xml. FDA 5030
- Promotional contact — the promotional labeling and advertising regulatory contact is in the envelope. FDA 1545
- Audience type — consumer or professional, set on 1.15. FDA 5039
- Material type and ID — on every material, the ID 30 characters at most. FDA 2012, 1550
- Issue date — on every 2253 material, written YYYYMMDD. FDA 1681, 1554
- Annotations only in 1.15 — annotated versions under the material, nowhere else. FDA 5055
Where everything goes
US regional DTD v3.3. The free PDF adds the document types and where 2253 submissions cause rework.
Carries the audience type: consumer or professional (required)
Cover letters, responses, and other correspondence with OPDP or APLB
Carries the document type: 2253, advisory request, presubmission or TV pre-dissemination (required)
One per piece. Carries the material type and material ID (required) and the issue date
Clean version, annotated version, annotated labeling and annotated references
The current product labeling, required with every 2253 submission
Form FDA 2253 — the only form in a promotional submission
Where 2253 submissions go wrong
Missing labeling
The current labeling goes in 1.14.6 every time, even when unchanged.
A second form
Form 2253 is the only form allowed in a promotional submission.
Long material IDs
Thirty characters at most. Internal job codes are often longer.
Missing issue dates
Required for every 2253 material, in YYYYMMDD.
Stray annotations
Annotated PDFs belong under the material in 1.15 only.
No promotional contact
The envelope needs the promotional contact type, not only the regulatory contact.
The Form 2253 eCTD checklist
For regulatory operations and advertising and promotion teams. Print it, or copy it into your own procedure.
- 15 checks with FDA rule numbers and severity
- Module 1.15, section by section
- The six promotional document types
- Where 2253 submissions cause rework, and practices that help
Frequently asked
What is Form FDA 2253?
The form a company uses to send FDA its advertisements and promotional labeling for prescription drugs and biologics at the time they are first used. Promotional submissions go to OPDP at CDER or APLB at CBER.
Where does promotional material go in an eCTD?
In Module 1.15. Correspondence goes in 1.15.1 and the materials in 1.15.2, one heading per material with its clean and annotated versions beneath it. Form 2253 goes in 1.1 and the current product labeling in 1.14.6.
Do I need to include labeling with a 2253 submission?
Yes. FDA’s validation criteria require the most current product labeling in section 1.14.6 of every 2253 submission (rule 1551, high severity).
What attributes does Module 1.15 need?
An audience type on 1.15 (consumer or professional), a document type on 1.15.2, and a material type and material ID on each material, with an issue date for 2253 materials. The material ID can be at most 30 characters.
Promotional submissions without the rework
DnXT Publisher’s Module 1.15 wizard takes the audience, document type, material type and ID from FDA’s own lists.